An Open-label, Multi-Center, Non-Randomised Phase I Dose-Escalation Study to Investigate the Safety and Tolerability of ONO-4059 (ONO/GS-4059) Given as Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL)
Latest Information Update: 18 Mar 2021
At a glance
- Drugs Tirabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 15 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 05 Nov 2015 Results published in the Blood
- 18 Aug 2015 Status changed from recruiting to active, no longer recruiting ClinicalTrials.gov record.